Obsidian Therapeutics, Inc. OBX
12.56 USD -0.32 (-2.48%)
Nov 12, 2026, 1:37 PM EST
12.00 Day range 13.04
9.60 52-week range 49.97
- YTD
- -28.23%
- 1 year
- -28.23%
News
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Karyopharm Therapeutics (NASDAQ:KPTI) stock moved upwards by 10.0% to $0.04 during Monday's after-market session. The company's market cap stands at $1.2 million. Fractyl Health (NASDAQ:GUTS)…
benzinga.com Dole Posts Downbeat Q3 Results, Joins NVIDIA And Other Big Stocks Moving Lower In Monday’s Pre-Market Session U.S. futures rose, but Dole fell 8.3% after missing Q3 estimates. CEVA, CYPH, CLNE, SMRT, OBX, ASST, NVDA and BMNR also declined premarket.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Obsidian Therapeutics (NASDAQ:OBX) stock increased by 27.7% to $12.26 during Friday's regular session. The company's market cap stands at $593.0 million. TransMedics Group (NASDAQ:TMDX)…
benzinga.com Obsidian Therapeutics To Present Updated Data In Participants With Immune-Checkpoint Inhibitor-Resistant Advanced Melanoma From Phase 1 Trial, Phase 1/2 Agni-01 Multicenter Trial Of Amsokigene Autoleucel At Society For Immunotherapy Of Cancer Obsidian Therapeutics, Inc. (NASDAQ:OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell…
businesswire.com Obsidian Therapeutics to Present Updated Amsoki-cel Efficacy and Pooled Safety Data in Advanced Melanoma at SITC 2026 Annual Meeting CAMBRIDGE, Mass.--(BUSINESS WIRE)--Obsidian Therapeutics, Inc. (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered…
benzinga.com Obsidian Therapeutics To Present Updated Data In Patients With Immune-Checkpoint Inhibitor-Resistant Advanced Melanoma From Its Phase 1 Study And The Phase 1/2 Agni-01 Multicenter Study Of Amsokigene Autoleucel Presentations at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, taking place in Phoenix, AZ, November 4-8, 2026. The poster presentation will summarize pooled safety data across…- benzinga.com Leerink Partners Initiates Coverage On Obsidian Therapeutics with Outperform Rating, Announces Price Target of $32 Leerink Partners initiates coverage on Obsidian Therapeutics (NASDAQ:OBX) with a Outperform rating and announces Price Target of $32.
benzinga.com Roivant Sciences, Pharvaris, IonQ And Other Big Stocks Moving Higher On Tuesday U.S. stocks fell Tuesday, but Roivant surged 16% on positive PH-ILD trial data. Pharvaris, Solaris, IonQ and quantum stocks also posted strong gains.
benzinga.com Duos Technologies Posts Upbeat Q2 Results, Joins Amylyx Pharmaceuticals, Weave Communications And Other Big Stocks Moving Higher On Tuesday US stocks down, Nasdaq falls 300+ points. Duos Tech shares rise on better Q2 results. Many other big stocks gain, including Duolingo, Intuit, and Newsmax.- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers iTonic Holdings (NASDAQ:ITOC) stock moved upwards by 32.0% to $0.41 during Friday's after-market session. The company's market cap stands at $4.9 million. Quanterix (NASDAQ:QTRX) shares…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Liminatus Pharma (NASDAQ:LIMN) stock increased by 48.4% to $0.16 during Thursday's regular session. The market value of their outstanding shares is at $7.2 million. BeyondSpring (NASDAQ:BYSI)…
benzinga.com This Civeo Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday Analysts change outlook on top Wall Street names, including initiations, upgrades, and downgrades. Check our analyst ratings page for details.- benzinga.com Obsidian Therapeutics Enrolls First Participant In Its Phase 1/2 Agni-01 Trial Of Amsokigene Autoleucel To Treat Advanced Or Metastatic Melanoma Obsidian Therapeutics, Inc. ("Obsidian") (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte…
- benzinga.com Piper Sandler Initiates Coverage On Obsidian Therapeutics with Overweight Rating, Announces Price Target of $42 Piper Sandler analyst Kelsey Goodwin initiates coverage on Obsidian Therapeutics (NASDAQ:OBX) with a Overweight rating and announces Price Target of $42.